S&P 500   4,219.15 (+0.94%)
DOW   33,121.38 (+0.65%)
QQQ   351.63 (+1.05%)
AAPL   179.80 (+1.44%)
MSFT   331.20 (+0.86%)
META   270.89 (+2.33%)
GOOGL   123.23 (+0.29%)
AMZN   122.90 (+1.92%)
TSLA   206.54 (+1.28%)
NVDA   395.17 (+4.45%)
NIO   7.60 (+0.93%)
BABA   83.02 (+4.36%)
AMD   120.05 (+1.56%)
T   15.83 (+0.64%)
F   12.08 (+0.67%)
MU   69.09 (+1.30%)
CGC   0.84 (+0.93%)
GE   104.76 (+3.18%)
DIS   88.81 (+0.97%)
AMC   4.63 (+2.89%)
PFE   38.05 (+0.08%)
PYPL   63.19 (+1.94%)
NFLX   404.56 (+2.36%)
S&P 500   4,219.15 (+0.94%)
DOW   33,121.38 (+0.65%)
QQQ   351.63 (+1.05%)
AAPL   179.80 (+1.44%)
MSFT   331.20 (+0.86%)
META   270.89 (+2.33%)
GOOGL   123.23 (+0.29%)
AMZN   122.90 (+1.92%)
TSLA   206.54 (+1.28%)
NVDA   395.17 (+4.45%)
NIO   7.60 (+0.93%)
BABA   83.02 (+4.36%)
AMD   120.05 (+1.56%)
T   15.83 (+0.64%)
F   12.08 (+0.67%)
MU   69.09 (+1.30%)
CGC   0.84 (+0.93%)
GE   104.76 (+3.18%)
DIS   88.81 (+0.97%)
AMC   4.63 (+2.89%)
PFE   38.05 (+0.08%)
PYPL   63.19 (+1.94%)
NFLX   404.56 (+2.36%)
S&P 500   4,219.15 (+0.94%)
DOW   33,121.38 (+0.65%)
QQQ   351.63 (+1.05%)
AAPL   179.80 (+1.44%)
MSFT   331.20 (+0.86%)
META   270.89 (+2.33%)
GOOGL   123.23 (+0.29%)
AMZN   122.90 (+1.92%)
TSLA   206.54 (+1.28%)
NVDA   395.17 (+4.45%)
NIO   7.60 (+0.93%)
BABA   83.02 (+4.36%)
AMD   120.05 (+1.56%)
T   15.83 (+0.64%)
F   12.08 (+0.67%)
MU   69.09 (+1.30%)
CGC   0.84 (+0.93%)
GE   104.76 (+3.18%)
DIS   88.81 (+0.97%)
AMC   4.63 (+2.89%)
PFE   38.05 (+0.08%)
PYPL   63.19 (+1.94%)
NFLX   404.56 (+2.36%)
S&P 500   4,219.15 (+0.94%)
DOW   33,121.38 (+0.65%)
QQQ   351.63 (+1.05%)
AAPL   179.80 (+1.44%)
MSFT   331.20 (+0.86%)
META   270.89 (+2.33%)
GOOGL   123.23 (+0.29%)
AMZN   122.90 (+1.92%)
TSLA   206.54 (+1.28%)
NVDA   395.17 (+4.45%)
NIO   7.60 (+0.93%)
BABA   83.02 (+4.36%)
AMD   120.05 (+1.56%)
T   15.83 (+0.64%)
F   12.08 (+0.67%)
MU   69.09 (+1.30%)
CGC   0.84 (+0.93%)
GE   104.76 (+3.18%)
DIS   88.81 (+0.97%)
AMC   4.63 (+2.89%)
PFE   38.05 (+0.08%)
PYPL   63.19 (+1.94%)
NFLX   404.56 (+2.36%)
NASDAQ:ACRX

AcelRx Pharmaceuticals (ACRX) Stock Forecast, Price & News

$1.02
+0.02 (+2.42%)
(As of 12:18 PM ET)
Compare
Today's Range
$0.99
$1.04
50-Day Range
$0.60
$1.11
52-Week Range
$0.55
$7.60
Volume
32,007 shs
Average Volume
194,925 shs
Market Capitalization
$11.14 million
P/E Ratio
0.15
Dividend Yield
N/A
Price Target
N/A

AcelRx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
7.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
0.90mentions of AcelRx Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.67) to ($2.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

917th out of 1,980 stocks

Pharmaceutical Preparations Industry

443rd out of 978 stocks


ACRX stock logo

About AcelRx Pharmaceuticals (NASDAQ:ACRX) Stock

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.

Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Stock News Headlines

AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
Acelrx (ACRX) Receives a Hold from H.C. Wainwright
See More Headlines

ACRX Price History

ACRX Company Calendar

Last Earnings
3/30/2023
Today
6/01/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRX
Employees
43
Year Founded
N/A

Profitability

Net Income
$47.76 million
Net Margins
2,696.50%
Pretax Margin
3,946.35%

Debt

Sales & Book Value

Annual Sales
$1.77 million
Book Value
$1.30 per share

Miscellaneous

Free Float
10,312,000
Market Cap
$10.88 million
Optionable
Optionable
Beta
0.25

Key Executives

  • Vincent J. Angotti
    President, Chief Executive Officer & Director
  • Raffi Asadorian
    Chief Financial & Accounting Officer
  • Pamela Pierce Palmer
    Director & Chief Medical Officer
  • Badri N. Dasu
    Chief Engineering Officer
  • Mark A. Evashenk
    Vice President-Clinical Operations













ACRX Stock - Frequently Asked Questions

How have ACRX shares performed in 2023?

AcelRx Pharmaceuticals' stock was trading at $2.26 at the beginning of 2023. Since then, ACRX stock has decreased by 55.9% and is now trading at $0.9960.
View the best growth stocks for 2023 here
.

Are investors shorting AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totaling 765,800 shares, a decrease of 10.5% from the April 30th total of 855,800 shares. Based on an average daily volume of 204,900 shares, the short-interest ratio is currently 3.7 days. Currently, 7.1% of the company's stock are sold short.
View AcelRx Pharmaceuticals' Short Interest
.

When is AcelRx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ACRX earnings forecast
.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) released its quarterly earnings data on Thursday, March, 30th. The specialty pharmaceutical company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.90. AcelRx Pharmaceuticals had a net margin of 2,696.50% and a negative trailing twelve-month return on equity of 93.99%.

When did AcelRx Pharmaceuticals' stock split?

AcelRx Pharmaceuticals shares reverse split on the morning of Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.37%), Simplex Trading LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Adrian Adams and Vincent J Angotti.
View institutional ownership trends
.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $1.00.

How much money does AcelRx Pharmaceuticals make?

AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $10.88 million and generates $1.77 million in revenue each year. The specialty pharmaceutical company earns $47.76 million in net income (profit) each year or $6.91 on an earnings per share basis.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500.

This page (NASDAQ:ACRX) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -